• Something wrong with this record ?

Evolocumab is Initiated in Central and Eastern Europe at Much Higher LDL-C Levels Than Recommended in Guidelines: Results from the Observational HEYMANS Study

V. Blaha, R. Margoczy, I. Petrov, A. Postadzhiyan, K. Rašlová, H. Rosolová, I. Bridges, NN. Dhalwani, M. Zachlederova, KK. Ray

. 2023 ; 28 (-) : 10742484231172847. [pub] -

Language English Country United States

Document type Journal Article, Observational Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc23010714

Purpose: We examined clinical characteristics and low-density lipoprotein cholesterol (LDL-C) lowering in patients initiating evolocumab in real-world practice in a Central and Eastern European (CEE) cohort from the pan-European HEYMANS study. Methods: Patients from Bulgaria, Czech Republic, and Slovakia were enrolled at initiation of evolocumab (baseline) as per local reimbursement criteria. Demographic/clinical characteristics, lipid-lowering therapy (LLT) and lipid values were collected from medical records for ≤6 months before baseline and ≤30 months after evolocumab initiation. Results: Overall, 333 patients were followed over a mean (SD) duration of 25.1 (7.5) months. At initiation of evolocumab, LDL-C levels were markedly elevated in all three countries, with a median (Q1, Q3) LDL-C of 5.2 (4.0, 6.6) mmol/L in Bulgaria, 4.5 (3.8, 5.8) mmol/L in the Czech Republic, and 4.7 (4.0, 5.6) mmol/L in Slovakia. Within the first three months of evolocumab treatment, LDL-C levels were reduced by a median of 61% in Bulgaria, 64% in the Czech Republic, and 53% in Slovakia. LDL-C levels remained low throughout the remaining period of observation. The 2019 ESC/EAS guideline-recommended risk-based LDL-C goals were attained by 46% of patients in Bulgaria, 59% in the Czech Republic, and 43% of patients in Slovakia. LDL-C goal attainment was higher in patients receiving a statin ± ezetimibe-based background therapy (Bulgaria: 55%, Czech Republic: 71%, Slovakia: 51%) compared to those receiving evolocumab alone (Bulgaria: 19%, Czech Republic: 49%, Slovakia: 34%). Conclusion: In the HEYMANS CEE cohort, patients initiated on evolocumab had baseline LDL-C levels approximately three-fold higher than guideline-recommended thresholds for PCSK9i initiation. Risk-based LDL-C goal attainment was highest in patients receiving high-intensity combination therapy. Lowering the LDL-C reimbursement threshold for PCSK9i initiation would allow more patients to receive combination therapy, thus improving LDL-C goal attainment. Trial registration: ClinicalTrials.gov (NCT02770131; registration date: 27 April 2016).

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010714
003      
CZ-PrNML
005      
20230801132607.0
007      
ta
008      
230718s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1177/10742484231172847 $2 doi
035    __
$a (PubMed)37218974
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Blaha, Vladimír $u 3rd Department of Internal Medicine - Metabolic Care and Gerontology, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic
245    10
$a Evolocumab is Initiated in Central and Eastern Europe at Much Higher LDL-C Levels Than Recommended in Guidelines: Results from the Observational HEYMANS Study / $c V. Blaha, R. Margoczy, I. Petrov, A. Postadzhiyan, K. Rašlová, H. Rosolová, I. Bridges, NN. Dhalwani, M. Zachlederova, KK. Ray
520    9_
$a Purpose: We examined clinical characteristics and low-density lipoprotein cholesterol (LDL-C) lowering in patients initiating evolocumab in real-world practice in a Central and Eastern European (CEE) cohort from the pan-European HEYMANS study. Methods: Patients from Bulgaria, Czech Republic, and Slovakia were enrolled at initiation of evolocumab (baseline) as per local reimbursement criteria. Demographic/clinical characteristics, lipid-lowering therapy (LLT) and lipid values were collected from medical records for ≤6 months before baseline and ≤30 months after evolocumab initiation. Results: Overall, 333 patients were followed over a mean (SD) duration of 25.1 (7.5) months. At initiation of evolocumab, LDL-C levels were markedly elevated in all three countries, with a median (Q1, Q3) LDL-C of 5.2 (4.0, 6.6) mmol/L in Bulgaria, 4.5 (3.8, 5.8) mmol/L in the Czech Republic, and 4.7 (4.0, 5.6) mmol/L in Slovakia. Within the first three months of evolocumab treatment, LDL-C levels were reduced by a median of 61% in Bulgaria, 64% in the Czech Republic, and 53% in Slovakia. LDL-C levels remained low throughout the remaining period of observation. The 2019 ESC/EAS guideline-recommended risk-based LDL-C goals were attained by 46% of patients in Bulgaria, 59% in the Czech Republic, and 43% of patients in Slovakia. LDL-C goal attainment was higher in patients receiving a statin ± ezetimibe-based background therapy (Bulgaria: 55%, Czech Republic: 71%, Slovakia: 51%) compared to those receiving evolocumab alone (Bulgaria: 19%, Czech Republic: 49%, Slovakia: 34%). Conclusion: In the HEYMANS CEE cohort, patients initiated on evolocumab had baseline LDL-C levels approximately three-fold higher than guideline-recommended thresholds for PCSK9i initiation. Risk-based LDL-C goal attainment was highest in patients receiving high-intensity combination therapy. Lowering the LDL-C reimbursement threshold for PCSK9i initiation would allow more patients to receive combination therapy, thus improving LDL-C goal attainment. Trial registration: ClinicalTrials.gov (NCT02770131; registration date: 27 April 2016).
650    _2
$a lidé $7 D006801
650    12
$a anticholesteremika $x škodlivé účinky $7 D000924
650    _2
$a LDL-cholesterol $7 D008078
650    12
$a statiny $x terapeutické užití $7 D019161
650    _2
$a výsledek terapie $7 D016896
651    _2
$a východní Evropa $x epidemiologie $7 D005061
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Margoczy, Roman $u Department of General Cardiology, Middle Slovak Institute of Cardiovascular Diseases, Banska Bystrica, Slovakia
700    1_
$a Petrov, Ivo $u Department of Cardiology, Clinic of Cardiology and Angiology, University Hospital Acibadem City Clinic and Sofia University "St. Kliment Ohridski", Sofia, Bulgaria
700    1_
$a Postadzhiyan, Arman $u Department of General Medicine, Medical University of Sofia, Sofia, Bulgaria
700    1_
$a Rašlová, Katarína $u Metabolic Center, LTD, Bratislava, Slovakia
700    1_
$a Rosolová, Hana $u 2nd Medical Department, Center of Preventive Cardiology, Charles University of Pilsen, Pilsen, Czechia
700    1_
$a Bridges, Ian $u Amgen Ltd, Uxbridge, UK
700    1_
$a Dhalwani, Nafeesa N $u Amgen Inc., Thousand Oaks, USA
700    1_
$a Zachlederova, Marie $u JCPT1172847Amgen s.r.o., Prague, Czech Republic
700    1_
$a Ray, Kausik K $u Department of Public Health and Primary Care, Imperial Centre for Cardiovascular Disease Prevention and Imperial Clinical Trials Unit, Imperial College London, London, UK
773    0_
$w MED00205904 $t Journal of cardiovascular pharmacology and therapeutics $x 1940-4034 $g Roč. 28, č. - (2023), s. 10742484231172847
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37218974 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132604 $b ABA008
999    __
$a ok $b bmc $g 1963262 $s 1196979
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 28 $c - $d 10742484231172847 $e - $i 1940-4034 $m Journal of cardiovascular pharmacology and therapeutics $n J Cardiovasc Pharmacol Ther $x MED00205904
LZP    __
$a Pubmed-20230718

Find record

Citation metrics

Archiving options